

Pascal Hammel

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4612425/pascal-hammel-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30 papers	1,212 citations	14 h-index	33 g-index
33 ext. papers	1,555 ext. citations	7.1 avg, IF	3.86 L-index

#	Paper	IF	Citations
30	Ovarian metastases of pancreatic adenocarcinoma: clinical presentation, role of surgery, and potential value of the mutational profile for the differential diagnosis with primary mucinous ovarian carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211053412	5.4	
29	Efficacy and tolerance of gemcitabine and nab-paclitaxel in elderly patients with advanced pancreatic ductal adenocarcinoma. <i>Pancreatology</i> , 2021 , 21, 1064-1064	3.8	1
28	Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO group. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021 , 45, 101607	2.4	0
27	Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020 , 26, 5208-5216	12.9	12
26	Gastrointestinal bleeding in patients with pancreatic cancer: Causes and haemostatic treatments. <i>United European Gastroenterology Journal</i> , 2020 , 8, 1106-1114	5.3	0
25	Cervical bone pain revealing a bone metastatic colon cancer: A case report. <i>Molecular and Clinical Oncology</i> , 2020 , 13, 2	1.6	
24	Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study. <i>Clinical Colorectal Cancer</i> , 2020 , 19, 39-47.e5	3.8	9
23	Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial. <i>European Journal of Cancer</i> , 2020 , 124, 91-101	7.5	40
22	PARP inhibition in treatment of pancreatic cancer. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 939-945	5.5	10
21	Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor. <i>Neuroendocrinology</i> , 2020 , 110, 83-91	5.6	24
20	Chemotherapy in Resected Neuroendocrine Carcinomas of the Digestive Tract: A National Study from the French Group of Endocrine Tumours. <i>Neuroendocrinology</i> , 2020 , 110, 404-412	5.6	7
19	Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study. <i>British Journal of Cancer</i> , 2019 , 120, 697-702	8.7	9
18	Appropriateness of pancreatic resection in high-risk individuals for familial pancreatic ductal adenocarcinoma: a patient-level meta-analysis and proposition of the Beaujon score. <i>United European Gastroenterology Journal</i> , 2019 , 7, 358-368	5.3	7
17	Comparison of Temozolomide-Capecitabine to 5-Fluorouracil-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses. <i>Neuroendocrinology</i> , 2019 , 108, 343-353	5.6	20
16	Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial. <i>Cancer Medicine</i> , 2019 , 8, 5078-5088	4.8	8
15	Role of endoscopic ultrasound in the screening and follow-up of high-risk individuals for familial pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2019 , 25, 5082-5096	5.6	7
14	Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations. <i>European Journal of Human Genetics</i> , 2018 , 26, 1732-1742	5.3	23

13	Biomarkers for the risk of thrombosis in pancreatic adenocarcinoma are related to cancer process. <i>Oncotarget</i> , 2018 , 9, 26453-26465	3.3	24
12	Screening and surveillance in hereditary gastrointestinal cancers: Recommendations from the European Society of Digestive Oncology (ESDO) expert discussion at the 20th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona, June 2018. <i>European Journal of Cancer</i> , 2018 , 181-84, 183	7.5	37
11	Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). <i>Digestive and Liver Disease</i> , 2018 , 50, 1257-1271	3.3	65
10	Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer. <i>International Journal of Cancer</i> , 2018 , 143, 2053-2064	7.5	44
9	Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 337-346	18.8	20
8	Evaluation and management of pancreatic lesions in patients with von Hippel-Lindau disease. <i>Nature Reviews Clinical Oncology</i> , 2016 , 13, 537-49	19.4	52
7	Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1844-53	27.4	538
6	Radiation Therapy Deviations in Trial of Locally Advanced Prostate Cancer-Reply. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 316, 1409-1410	27.4	
5	Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGE0 prospective multicentre cohort. <i>British Journal of Cancer</i> , 2015 , 113, 989-95	8.7	121
4	State of the art and future directions of pancreatic ductal adenocarcinoma therapy. <i>Pharmacology & Therapeutics</i> , 2015 , 155, 80-104	13.9	66
3	A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial. <i>BMC Cancer</i> , 2015 , 15, 653	4.8	8
2	Rationale and design of the Adapted Physical Activity in advanced Pancreatic Cancer patients (APACaP) GERCOR (Groupe Coopérateur Multidisciplinaire en Oncologie) trial: study protocol for a randomized controlled trial. <i>Trials</i> , 2015 , 16, 454	2.8	12
1	Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma. <i>Pancreas</i> , 2015 , 44, 1141-7	2.6	48